Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 18

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 18
---
 MacGregor brings extensive experience as a global pharmaceuticals executive to our Board, including significant experience as a vaccine executive Ms. Silvernail brings substantial corporate finance, M&A, capital markets, and business development expertise through experience as an executive and Board member in the life sciences industry © Copyright DYNAVAX 2025

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Deep Track’s Plan Threatens Growth and Puts Future Stockholder Value at Risk 25 |

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Deep Track’s One - Dimensional “Plan” Threatens Stockholder Value © Copyright DYNAVAX 2025 Our Strategy Deep Track’s “Plan” 26 | Monetize HEPLISAV - B exclusively for capital return by over - levering the Company with high - cost debt Shutter efforts to accelerate growth with internal and external opportunities Return all cash to stockholders Drive growth in HEPLISAV - B Advance differentiated vaccine pipeline using core technology Identify strategic opportunities to accelerate growth leveraging our fully integrated business platform Opportunistically return capital to stockholders 1 2 3 4 Deep Track’s one - dimensional plan to strip - mine Dynavax jeopardizes our significant long - term growth opportunities in exchange for a near - term payoff at considerably lower value

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx O Monetize HEPLISAV - B exclusively for capital return by over - levering the Company with high - cost debt Increases risk to single - product company and asset in highly competitive landscape and challenging macro environment O Shutter efforts to accelerate growth with internal and external opportunities Underutilizes Dynavax’s core capabilities to bring important medicines/vaccines to patients where we already have a successful track record O Return all cash to stockholders Starves our